Bluejay Diagnostics (NASDAQ:BJDX) Director Donald Chase Purchases 12,500 Shares

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Director Donald Chase acquired 12,500 shares of Bluejay Diagnostics stock in a transaction that occurred on Saturday, March 14th. The shares were purchased at an average price of $2.00 per share, for a total transaction of $25,000.00. Following the completion of the purchase, the director directly owned 12,525 shares of the company’s stock, valued at $25,050. The trade was a 50,000.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Bluejay Diagnostics Price Performance

Shares of BJDX opened at $1.72 on Tuesday. The business’s fifty day moving average price is $1.90 and its 200 day moving average price is $3.19. Bluejay Diagnostics, Inc. has a 12-month low of $1.63 and a 12-month high of $16.68. The stock has a market capitalization of $1.78 million, a PE ratio of -0.15 and a beta of 0.72.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.95) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics as of its most recent filing with the Securities and Exchange Commission (SEC). 18.47% of the stock is currently owned by institutional investors and hedge funds.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.